A Qualitative Study on Barriers to COVID-19 Vaccine Uptake among Community Members in Tanzania.
COVID-19
COVID-19 vaccines
Tanzania
barriers
facilitators
perceptions
qualitative
vaccine hesitancy
vaccine uptake
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
15 Aug 2023
15 Aug 2023
Historique:
received:
05
05
2023
revised:
02
06
2023
accepted:
21
06
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The use of vaccines is one of the key tools in reversing the COVID-19 pandemic; however, various reports reported the low uptake of the vaccines. This study explored the barriers to the COVID-19 vaccine uptake among community members in Tanzania. A qualitative explorative study was conducted in December 2021 and April 2022 in eight regions of Tanzania. Focus group discussions (FGDs) and in-depth interviews (IDIs) were the methods of data collection. A total of 48 FGDs and 32 IDIs were conducted. Participants were aware of the COVID-19 disease and vaccines. The barriers to the COVID-19 vaccine non-uptake included receiving contradicting statements from top government leaders, vaccine preceded the education, myths towards vaccines, the presence of different types of vaccines, the process of getting the vaccine, the influence of social media and random people from the community, and vaccine conflicting religious beliefs. Despite being aware of the vaccine, the uptake of the COVID-19 vaccine is still low. Interventions that focus on increasing community knowledge about COVID-19 vaccines and addressing myths about the vaccines are needed.
Identifiants
pubmed: 37631934
pii: vaccines11081366
doi: 10.3390/vaccines11081366
pmc: PMC10458528
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : UNICEF and AMREF
ID : TZA/PCA2022126/PD2022203
Références
Front Public Health. 2022 Oct 10;10:997884
pubmed: 36324470
PLoS One. 2022 Jun 16;17(6):e0269923
pubmed: 35709076
Hum Vaccin Immunother. 2020 Nov 1;16(11):2586-2593
pubmed: 32693678
BMJ Open. 2022 May 30;12(5):e052432
pubmed: 35636790
BMC Med. 2022 May 23;20(1):200
pubmed: 35606843
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
PLoS One. 2022 May 18;17(5):e0268711
pubmed: 35584110
Trop Med Infect Dis. 2022 Jul 11;7(7):
pubmed: 35878142
Vaccines (Basel). 2023 Feb 17;11(2):
pubmed: 36851342
Glob Health Res Policy. 2022 Jul 19;7(1):21
pubmed: 35850783
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067682
Nat Med. 2023 Feb;29(2):366-375
pubmed: 36624316
BMC Geriatr. 2022 Apr 6;22(1):288
pubmed: 35387602
Hum Vaccin Immunother. 2023 Dec 31;19(1):2191576
pubmed: 37017234
Hum Vaccin Immunother. 2022 Dec 31;18(1):2034457
pubmed: 35240908
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Wkly Epidemiol Rec. 2014 Dec 12;89(50):561-76
pubmed: 25513671
J Infect. 2021 Nov;83(5):559-564
pubmed: 34437927
Vaccines (Basel). 2022 Aug 30;10(9):
pubmed: 36146507
BMC Public Health. 2023 Jan 31;23(1):205
pubmed: 36721158
Clin Epidemiol Glob Health. 2022 Mar-Apr;14:100981
pubmed: 35187292
J Med Internet Res. 2022 Aug 4;24(8):e37367
pubmed: 35816685